Acute Neurological ICU Sedation Trial (ANIST)
Completed · Phase 2
Conditions studied: Sedation
In brief
Dexmedetomidine (Precedex, Hospira) is a "super" selective alpha2-agonist - 8-10x more avid binding to alpha2 receptors than clonidine - and may have particularly favorable characteristics as a continuous i.v. infusion sedative for critically ill neuroscience patients. Its combination of anxiolysis, analgesia, without undue lethargy may make it an ideal agent where frequent neurological examinations are important. Unclear, however, is whether Precedex is superior to current common i.v. sedation protocols, and if there are any undue concerns of this agent on cerebral physiology and cortical stimulation.
Key facts
- Study ID
- NCT00390871
- Run by
- Johns Hopkins University
- People needed
- 35
- Starts
- 2005-05-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2019-05-16
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Johns Hopkins University — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.